OpenAI acquires Orchestra Bio to bring AI agents into drug development

OpenAI has acquired Orchestra Bio, according to a report originally published by SiliconANGLE. The acquisition is aimed at bringing AI agents into drug development, extending OpenAI’s work in artificial intelligence into a sector where software is increasingly used to support research and scientific workflows.

AI agents generally refer to AI systems designed to carry out multistep tasks with varying degrees of autonomy. In drug development, such tools could be applied to information-intensive processes, including organizing research data, assisting scientific analysis and helping teams navigate complex development workflows. Drug development involves lengthy research, testing and regulatory processes, making it a significant target for automation and computational tools.

The reported deal highlights continued interest in using generative AI and agent-based systems beyond consumer-facing applications. OpenAI’s acquisition of Orchestra Bio signals a focus on applying AI capabilities to life sciences, where technology companies and pharmaceutical researchers are exploring how AI can support discovery and development work. SiliconANGLE did not provide further details in the available report summary about the transaction’s financial terms, timeline or planned product integration.